Asthma patients given risky levels of steroid tablets

More than one quarter of asthma patients have been prescribed potentially dangerous amounts of steroid tablets, with researchers warning this puts them at greater risk of serious side-effects.

Researchers, led by  University of Queensland Professor John Upham, analysed data from the Pharmaceutical Benefits Scheme (PBS) to find out how often Australians with asthma were taking repeated courses of steroid tablets.

Professor Upham said the study looked at more than 120,000 cases where asthma patients were given one or more prescriptions for steroid tablets by their doctor between 2014 and 2018.

“Researchers found more than 25 per cent of those patients were more likely to have a chronic condition,” Professor Upham said.

“Short courses of steroid tablets can be effective at treating asthma attacks in the short term, but it’s becoming clear that repeated use may cause significant long term side-effects like diabetes, osteoporosis and cataracts.

Around 2.5 million Australians have asthma, with the condition affecting more women than men.

Professor Upham said the best way to prevent asthma attacks was by regularly using preventer inhalers.

“Unfortunately, our study found half of asthma patients given repeated scripts for steroid tablets were not using inhalers as often as they should,” he said.

“Better approaches are needed to educate and support asthma patients, and encourage them to use preventer inhalers regularly.

“This is the best way to avoid or minimise the need for steroid tablets, and the side effects they can produce.”

Researchers from the Alfred Hospital (Melbourne), University of Newcastle, Monash University, Fiona Stanley Hospital (Perth), University of Sydney, Australian National University and Concord Hospital (Sydney) were involved in the study.

The paper was published in the Medical Journal of Australia. DOI: 10.5694/mja2.50758

Media: Professor John Upham, j.upham@uq.edu.au Faculty of Medicine Communications, med.media@uq.edu.au, +61 7 3365 5133, +61 436 368 746.